Unprecedented Growth Opportunity BIOTECHNOLOGY. Biotechnology India - An Overview Market and...
-
Upload
magnus-reynard-hudson -
Category
Documents
-
view
218 -
download
0
Transcript of Unprecedented Growth Opportunity BIOTECHNOLOGY. Biotechnology India - An Overview Market and...
Biotechnology
India - An Overview
Market and Growth Potential
Players
Opportunities
Why India?
Contact in India
India - An Introduction
Population
States/UTs
Geographical Area
Languages recognised
Business language
Per Capita Income**
GDP**
Over 1 bn
35
3.3 mn sq kms
22
English
US$ 534
US$ 650 bn**(at factor cost & at current prices)
1USD=43.54 INR (as on July 4, 2005)Source:CSO Statistics
India - Fast pace Growth
Largest democracy
4th largest economy by PPP index
6th largest energy consumer
ForEx reserves skyrocket from US$ 42 bn (2001) to
US$ 133 bn (February, 2005)
GDP growth to continue between 6-8%
3rd largest economy by 2050: Goldman Sachs
Leading in IT & BPO
Oil & Gas and Biotechnology sunrise industries
India - Leading the world
Hero Honda - largest manufacturer of motorcycles
Moser Baer - 3rd largest optical media
manufacturer in world
Pharmaceutical Industry - 4th largest in world
Walmart, GAP, Hilfiger sources more than
USD 1bn worth apparel from India
100 Fortune 500 have set R&D facilities in India
including GE, Delphi, Eli Lilly, HP, Heinz and Daimler
Chrysler
Biotechnology
India - An Overview
Market and Growth Potential
Players
Opportunities
Why India?
Contact in India
Biotech Market - Dynamic and growing
Size (2004-05) US$ 1090.5 mn
Largest segment Biopharma
Revenue from exports (2003-04) 56%
Total investment (2003-04) US$ 137 million Rate of growth over 202-2003 26%
Bio Agri6.95%
Bio Pharma75.24 %
Bio Services8.95%
Bio-IT2.09 %
Biopharma leads the way
Composition of Indian Biotech Sector (2004-05)
Bio Industrial6.74%
Source:Biospectrum-ABLE Survey
Market - A consistent uptrend
2002-03
2010
25% growth in investment
70% growth in employment
74% growth in R&D manpower
10% of global industry
1 million skilled jobs
US$ 5 billion annual revenues
Source: Confederation of Indian Industry (CII)
Biotechnology
India - An Overview
Market and Growth Potential
Players
Opportunities
Why India?
Contact in India
Biotechnology
India - An Overview
Market and Growth Potential
Players
Opportunities
Why India?
Contact in India
Year US$ millionGrowth
(%)
2000-01 54
2001-02 108.9 102
2002-03 137.2 26
Investments
• Annual investments in this sector will be of the order of US$ 150 mn and are growing at the rate of 25%.
• An additional investment of US$ 216 mn is expected in FY2005
Vaccine Sales of US$ 383.6 mn (2004-05)
Therapeutic Marketing licenses granted for over 25 recombinant therapeutic proteins
Diagnostics Sales market - US$ 138.2 mn (2004-05)
Invest in Biopharmaceuticals
India: The Vaccine Hub
• Indian firms estimated to supply 90% of global demand for the measles vaccine, in the near future.
• Serum Institute, Pune is believed to be the world`s largest manufacturer of DPT vaccines.
• Indian Immunologicals operates the world`s second largest plant for veterinary vaccines and is also the world`s largest manufacturer of the vaccine against Foot and Mouth Disease.
Invest in Biopharmaceuticals
Therapeutic Accounts for 14% of total biopharma sales (2004-05)
Diagnostics Forecast to grow by 35-40% in 2005 Immuno diagnostic market to increase
4 to 5 folds by 2005
Invest in Bioinformatics
By 2006 bionformatics market to grow
2004-05 US$ 22.9 mn
By 2006 US$ 120 mnSource: International Data Corporation (IDC)
Opportunities for
investment
Data mining
Gene annotation
Software bioinformatics
interface development
Quality
Speed
Technology
Disease Profile
Investigators
Genetic diversity
Ethics
Quality guidelines conformed
Patient enrolment rates upto six times
higher than US
CROs to benefit from India’s IT
strengths in data management
High incidence of infectious/lifestyle
diseases
Excellent pool of qualified & trained
doctors and physicians
Clinical Trials - Destination India
Biotechnology
India - An Overview
Market and Growth Potential
Players
Opportunities
Why India?
Contact in India
The India Advantage
Trained manpower and knowledge base
Rich biodiversity Extensive clinical trials opportunities
Excellent network of research laboratories
Well-developed base industries
40 National Research Institutes
300 life sciences colleges
120 medical colleges
200 biotech companies
100 teaching hospitals
The Infrastructure Advantage
15,000 scientists
500,000 graduates per annum
17,500 medical graduates per annum
Employing 25,000 scientists in R&D
Employing medical & paramedical professionals
The R & D Advantage
Genetic Engineering
DNA technologies
New Drug Delivery Systems
Rational drug design
Stem cell research
Bioinformatics
Biotech
R&D
strengths
spread
across
range of
segments
The Policy Advantage
India has transitioned from a process patent regime to a product
patent regime w.e.f January, 2005
150% weighted deduction on R&D expenditure
Single window application processing proposed by DBT
New biotech proposals to be cleared within 150 days
Formation of a SME Growth Fund to provide equity support to
small & medium units in the biotechnology sectors (Union Budget
2005-06)
Union Budget 2005-06
Benefits enjoyed by Export Oriented Units (EOU) extended
to Biotech Parks
- 100% FDI permitted through automatic route
- BTP units exempt from payment of Income Tax
- Export proceeds to be realised within 12 months
- BTPs allowed to retain 100% export earnings in the EEFC
account
The Biotech Park Advantage
Biotechnology
India - An Overview
Market and Growth Potential
Players
Opportunities
Why India?
Contact in India
Contact in India
Confederation of Indian Industry (CII)
23 Institutional AreaLodi RoadNew Delhi 110003
Tel 0091 11 24629994 - 7Fax 0091 11 24626149/24615693E-mail [email protected]